SEGMENT INFORMATION (Tables)

12 Months Ended

Dec. 31, 2018

Segment revenues and profits for the years ended December 31, 2018, 2017 and 2016 were as follows:



(in millions)	2018			2017			2016
Revenues:
Bausch + Lomb/International	$	4,664		$	4,795		$	4,857
Salix	1,749			1,566			1,530
Ortho Dermatologics	625			725			949
Diversified Products	1,342			1,638			2,338
Total revenues	$	8,380		$	8,724		$	9,674
Segment profit:
Bausch + Lomb/International	$	1,330		$	1,412		$	1,456
Salix	1,149			935			946
Ortho Dermatologics	265			336			408
Diversified Products	1,004			1,112			1,712
Total segment profit	3,748			3,795			4,522
Corporate	(605		)	(562		)	(690		)
Amortization of intangible assets	(2,644		)	(2,690		)	(2,673		)
Goodwill impairments	(2,322		)	(312		)	(1,077		)
Asset impairments	(568		)	(714		)	(422		)
Restructuring and integration costs	(22		)	(52		)	(132		)
Acquired in-process research and development costs	(1		)	(5		)	(34		)
Acquisition-related contingent consideration	9			289			13
Other income (expense)	21			353			(73		)
Operating (loss) income	(2,384		)	102			(566		)
Interest income	11			12			8
Interest expense	(1,685		)	(1,840		)	(1,836		)
Loss on extinguishment of debt	(119		)	(122		)	—
Foreign exchange and other	23			107			(41		)
Loss before benefit from income taxes	$	(4,154	)	$	(1,741	)	$	(2,435	)

Schedule of capital expenditures, depreciation and amortization by segment

Capital expenditures by segment for the years ended December 31, 2018, 2017 and 2016 were as follows:



(in millions)	2018		2017		2016
Capital expenditures:
Bausch + Lomb/International	$	139	$	159	$	221
Salix	2		3		2
Ortho Dermatologics	1		2		1
Diversified Products	2		4		5
	144		168		229
Corporate	13		3		6
Total capital expenditures	$	157	$	171	$	235

Schedule of revenues by product and by product category

Revenues by segment and product category were as follows:



(in millions)	Bausch + Lomb/ International						Salix							Ortho Dermatologics						Diversified Products						Total
	2018		2017		2016		2018			2017		2016		2018		2017		2016		2018		2017		2016		2018		2017		2016
Pharmaceuticals	$	892	$	956	$	966	$	1,752		$	1,564	$	1,529	$	465	$	571	$	806	$	923	$	1,286	$	1,865	$	4,032	$	4,377	$	5,166
Devices	1,505		1,421		1,407		—			—		—		135		111		97		—		—		—		1,640		1,532		1,504
OTC	1,412		1,529		1,581		—			—		—		—		—		—		—		—		—		1,412		1,529		1,581
Branded and Other Generics	784		819		830		—			—		—		—		—		—		403		338		455		1,187		1,157		1,285
Other revenues	71		70		73		(3		)	2		1		25		43		46		16		14		18		109		129		138
	$	4,664	$	4,795	$	4,857	$	1,749		$	1,566	$	1,530	$	625	$	725	$	949	$	1,342	$	1,638	$	2,338	$	8,380	$	8,724	$	9,674

Schedule of revenues and long-lived assets by geographic region

Revenues are attributed to a geographic region based on the location of the customer for the years ended December 31, 2018, 2017 and 2016 were as follows:



(in millions)	2018		2017		2016
U.S. and Puerto Rico	$	5,011	$	5,225	$	6,247
China	361		331		300
Canada	319		326		320
Japan	226		223		232
Poland	218		201		140
Mexico	211		201		189
France	205		188		186
Egypt	178		152		196
Germany	170		157		157
Russia	154		200		165
United Kingdom	117		108		104
Italy	85		78		72
Spain	83		77		70
Other	1,042		1,257		1,296
	$	8,380	$	8,724	$	9,674

Schedule of assets by geographic region

Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December 31, 2018 and 2017 were as follows:



(in millions)	2018		2017
U.S. and Puerto Rico	$	593	$	599
Ireland	217		235
Canada	99		98
Poland	94		100
Germany	66		70
Egypt	50		47
Mexico	48		50
France	31		34
Serbia	28		30
China	25		28
Italy	23		23
South Korea	14		15
Other	65		74
	$	1,353	$	1,403

Schedule of external customers that accounted for 10% or more of total revenues

Customers that accounted for 10% or more of total revenues were as follows:



	2018	2017	2016
AmerisourceBergen Corporation	18%	15%	13%
McKesson Corporation	18%	19%	21%
Cardinal Health, Inc.	13%	13%	15%